AKT1 and hepatocellular carcinoma: In addition, ETS reversed the effect of LAPTM4B-35 overexpression on the levels of c-myc, B-Cell CLL/lymphoma 2 Bcl-2, BCL2-associated X protein (Bax), cyclinD1, and p-AKT molecules in HCC cells, marking LAPTM4B-35 as a candidate for targeted therapy in HCC (112).